PaxMedica (NASDAQ:PXMD – Get Free Report) will likely be posting its resultson Wednesday, September 2nd. Analysts expect PaxMedica to announce earnings of ($0.88) per share for the quarter.
PaxMedica Price Performance
PaxMedica stock opened at $0.00 on Monday. PaxMedica has a 12-month low of $0.00 and a 12-month high of $0.02. The company has a market capitalization of $7,918.40, a PE ratio of -0.00 and a beta of -0.99.
PaxMedica Company Profile
PaxMedica, Inc is a clinical?stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation.
The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges.
Read More
- Five stocks we like better than PaxMedica
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.
